<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR7">
 <label>7.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Yau</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Park</surname>
    <given-names>JW</given-names>
   </name>
   <name>
    <surname>Finn</surname>
    <given-names>RS</given-names>
   </name>
   <name>
    <surname>Cheng</surname>
    <given-names>A-L</given-names>
   </name>
   <name>
    <surname>Mathurin</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Edeline</surname>
    <given-names>J</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>LBA38_PRCheckMate 459: a randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)</article-title>
  <source>Ann Oncol</source>
  <year>2019</year>
  <volume>30</volume>
  <issue>suppl_5</issue>
  <fpage>v851</fpage>
  <lpage>v934</lpage>
 </element-citation>
</ref>
